Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.

The oncologist - 1 Oct 2020

Huo Ran, Li Jinghua, Li Xiaofang, Shi Junping, Wang Kunjie, Jiao Jin, Shang Yanhong

Abstract excerpt

BACKGROUND: The identification of epidermal growth factor receptor (EGFR) mutations represents a milestone in the treatment of advanced non-small cell lung cancer. Patients with lung adenosquamous carcinomas (ASCs) rarely present with germline EGFR T790M mutation. The optimal treatment for cancers with germline EGFR T790M mutation (especially ASC) is not clear. MATERIALS AND METHODS: Using next-generation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds
Share to Carcinoma, Adenosquamous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Germ Cells

Share to Germ-Line Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 32367600
DOI: 10.1634/theoncologist.2019-0938
PMCID: PMC7543298

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.PMID 32367600Read ↗

Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutationsSemantic proximity Read ↗

Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.Semantic proximity Read ↗

Comprehensive analyses of genomic features and mutational signatures in adenosquamous carcinoma of the lungSemantic proximity Read ↗

Clinical Outcomes of Different Generations of EGFR Tyrosine Kinase Inhibitors in Advanced Lung Adenosquamous Carcinoma.Semantic proximity Read ↗

Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.Semantic proximity Read ↗

Establishment and characterization of a novel sinonasal adenosquamous carcinoma cell line, TC717, with a high tumor mutational burden.Semantic proximity Read ↗

Next-generation sequencing clarified why first-line treatment with osimertinib was ineffective in an autopsied case of EGFR-mutated lung squamous cell carcinoma.Semantic proximity Read ↗

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review.Semantic proximity Read ↗

Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?Semantic proximity Read ↗

EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.Semantic proximity Read ↗

Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.Semantic proximity Read ↗

EGFR gene mutations in patients with adenosquamous lung carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.